Skip to content
Screener

Innoviva, Inc. INVA Cost Reimbursement — Revenue

Other product segments

Giapreza
$22.3M+28.7%

Similar metrics at other companies

Hilton Grand Vacations logo
HGVCost reimbursements — Revenue
$149M+12.0%
DigitalBridge Group logo
DBRGCost Reimbursements — Revenue
$1.3M-45.8%
Natural Grocers by Vitamin Cottage logo
NGVCVendor Reimbursements — Revenue
$2.33M+17.7%
Hilton Worldwide logo
HLTReimbursement Revenue — Revenue
$1.98B+9.4%
Resources Connection, Inc. logo
RGPReimbursements — Revenue
$1.2M+9.1%
CRD
CRD.AReimbursements — Revenue
$10.6M-6.2%

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.53B+33.1%
Enterprise value$1.22B+2.1%
P/E4.3×-25.4×
P/S3.5×+0.4×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235

La Jolla also entered into the PAION commercial supply agreement (the “PAION Supply Agreement”) whereby La Jolla supplies PAION a minimum quantity of GIAPREZA® and XERAVA® until the earlier of July 13, 2027, or until a new supply agreement is executed. During the term of the supply agreement, we are reimbursed for direct and certain indirect manufacturing costs at cost. Cost reimbursements under the PAION Supply Agreement were $1.8 million for the three and six months ended June 30, 2026, and $0.8 million and $1.4 million for the three and six months ended June 30, 2025, respectively.

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s cost reimbursement — revenue?
Innoviva, Inc. (INVA) reported cost reimbursement — revenue of $1.8M in Q2 2026.
How has Innoviva, Inc.'s cost reimbursement — revenue changed year-over-year?
Innoviva, Inc.'s cost reimbursement — revenue increased by 125.0% year-over-year, from $800K to $1.8M.
What is the long-term trend for Innoviva, Inc.'s cost reimbursement — revenue?
Over 2 years (2023 to 2025), Innoviva, Inc.'s cost reimbursement — revenue has grown at a 44.1% compound annual growth rate (CAGR), from $1.3M to $2.7M.
What does cost reimbursement — revenue mean?
This metric represents the total revenue generated from cost reimbursement arrangements within the company's specific business segment. It reflects the recovery of expenses incurred during the delivery of specialized services or the management of strategic healthcare assets. Monitoring this revenue stream helps investors assess the company's ability to monetize operational support activities and recover costs associated with its broader portfolio of healthcare interests.

Ask your AI about Innoviva, Inc.'s cost reimbursement — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude